NVO: 6-K company filing

6-K 1 f6k_080626.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 August 6, 2026 NOVO NORDISK A/S (Exact name of Registrant as specified in its charter) Novo Allé 1 DK- 2880, Bagsvaerd Denmark (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F Form 20-F ☒ Form 40-F ☐ Trading in Novo Nordisk shares by board members, executives and associated persons Bagsværd, Denmark, 6 August 2026 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk. 1 Details of the person discharging managerial responsibilities/person closely associated a) Name of the Board member/Executive/Associated Person DÉSIRÈE JANTZEN ASGREEN 2 Reason for the notification a) Position/status Member of the Board of Directors b) Initial notification/Amendment Initial notification 3 Details of the issuer a) Name Novo Nordisk A/S b) LEI 549300DAQ1CVT6CXN342 4 Details of the transaction(s) a) Description of the financial instrument, type of instrument, Shares Identification code Novo Nordisk B DK0062498333 b) Nature of the transaction Other transaction (vesting of shares in accordance with Restricted Shares programme – Novo Nordisk 100th Anniversary Shares) c) Price(s) and volume(s) Price(s) Volume(s) DKK 294.30 7